MLTX
Strong SellSinkerMoonLake Immunotherapeutics · Healthcare · Switzerland · $1.3B · Avg Vol: $19M/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT MOONLAKE IMMUNOTHERAPEUTICS
Read
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory diseases. The company's lead asset, sonelokimab, is a nanobody targeting IL-17A/F, designed for conditions like hidradenitis suppurativa and psoriatic arthritis. Its innovative nanobody platform offers potential for differentiated efficacy and safety profiles in challenging immunological indications.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 19.0M | — |
| EPS | -0.60 | -0.73 | -1.89 | -3.53 | — | -3.84 | -3.38 | -3.33 | — |
| Shares | 83.6M | 60.5M | 63.1M | 71.4M | -14.6% | 85.1M | — | — | — |
| Debt | 0.3M | 3.7M | 2.8M | 75.7M | 544.7% | 101.5M | — | — | — |
| Equity | 48.9M | 495.7M | 446.8M | 304.5M | 84.0% | — | — | — | — |
| Op CF | -55.9M | -42.8M | -116.6M | -196.0M | — | -225.2M | — | — | — |
| Inv CF | -32.3M | -25.2M | -205.6M | 203.0M | — | — | — | — | — |
| Fin CF | 119.7M | 479.7M | 51.3M | 146.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MLTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MLTX | MoonLake Immunotherapeutics(you) | $1.3B | 8 | Strong Sell |
| OCS | Oculis Holding AG | $678M | 6 | Strong Sell |
| IDIA.SW | Idorsia Ltd | $1.7B | 22 | Sell |
| PHVS | Pharvaris N.V. | $2.5B | 21 | Sell |
| ACIU | AC Immune SA | $299M | 13 | Strong Sell |
| CRSP | CRISPR Therapeutics AG | $5.6B | 20 | Sell |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $290M | 20 | Sell |
| MOLN | Molecular Partners AG | $172M | 19 | Strong Sell |
| BANB.SW | Bachem Holding AG | $7.1B | 53 | Hold |
| BSLN.SW | Basilea Pharmaceutica AG | $986M | 97 | Strong Buy |
Peer medians: ROE 11.1% · P/E 29.9x · Gross margin 60.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.